



Published in final edited form as:

Wiley Interdiscip Rev Dev Biol. 2012 January ; 1(1): 114–137. doi:10.1002/wdev.1.

FROM GENES TO FUNCTION : THE *C. ELEGANS* GENETIC TOOLBOX

Thomas BOULIN and

Institut de Biologie de l'École Normale Supérieure, Biology Department, F-75005 Paris, France. Inserm, Unité 1024, F-75005 Paris, France. Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, F-75005 Paris, France

Oliver HOBERT

Columbia University Medical Center, HHMI, New York, USA

Thomas BOULIN: boulin@biologie.ens.fr

Abstract

This review aims to provide an overview of the technologies which make the nematode *Caenorhabditis elegans* an attractive genetic model system. We describe transgenesis techniques and forward and reverse genetic approaches to isolate mutants and clone genes. In addition, we discuss the new possibilities offered by genome engineering strategies and next generation genome analysis tools.

Introduction

The modern era of *C. elegans* research began less than fifty years ago when Sydney Brenner settled on the small nematode to tackle an ambitious goal laid out in his seminal paper published in 1974: “Some eight years ago, [...] I decided that what was needed was an experimental organism which was suitable for genetical study and in which one could determine the complete structure of the nervous system. *Drosophila*, with about 10^5 neurons, is much too large, and, looking for a simpler organism, my choice eventually settled on the small nematode, *Caenorhabditis elegans*”.¹ From the start, Brenner outlined a methodology that still prevails today: “One experimental approach to these problems is to investigate the effects of mutations on nervous systems. In principle, it should be possible to dissect the genetic specification of a nervous system in much the same way as was done for biosynthetic pathways in bacteria [...]”.¹ In the following years, Brenner and his colleagues completed a series of major projects that laid the foundations for *C. elegans* research: (1) they established the genetics of *C. elegans* and performed the first large scale mutant screens;¹ (2) they described the complete and largely invariant lineage of all 959 somatic *C. elegans* cells (plus 131 cells that die by programmed cell death) using standard light microscopy;^{2, 3} (3) they achieved the complete reconstruction of the adult nervous system by using electron micrographs of serial sections.⁴

Over the years, a number of discoveries added considerable attractiveness to *C. elegans* as a biological model organism. One important advance was the generation of transgenic animals, achieved through an efficient transgenesis technique developed in 1991 by Mello *et al.*⁵ and still in use to this day. In 1994, GFP reporter technology introduced by Martin Chalfie, allowed the visualization of gene expression patterns, as well as protein localization in live animals.⁶ In 1998, the discovery of genetic interference by double-stranded RNA (RNAi)⁷ enabled alternative approaches for large scale genetic screens. In the same year, the completion of the *C. elegans* genome sequence⁸ provided the first comprehensive view over the complete genomic landscape of a metazoan organism. This review aims to describe the

genetic toolbox available to *C. elegans* researchers by focusing on classical and novel techniques used for forward and reverse genetic analysis and recent developments in genome engineering by homologous recombination.

FORWARD GENETICS

Forward genetic screens in *C. elegans* have provided key mechanistic insights into deeply conserved developmental, homeostatic and pathogenic processes (see www.wormbook.org). We will describe here the different methods which can be used to generate and clone mutants from forward genetic screens. Previous monographs have discussed some of the more traditional methods in more detail (wormbook.org and ^{9, 10}).

Random mutagenesis with chemical and physical mutagens

Random mutations can be generated by exposing worms to mutagenic agents such as EMS (Ethyl methanesulfonate), ENU (N-ethyl-N-nitrosourea) or trimethylpsoralen followed by ultraviolet light activation (TMP/UV).⁹ EMS is the most popular mutagen in *C. elegans*. It alkylates primarily guanine residues leading to mispairing during replication: alkylated G pairs to T instead of C. The resulting mutations are mainly G/C to A/T transitions. EMS also introduces deletions, yet at much lower frequency than point mutations. ENU is also a potent mutagen which generates transversions in addition to transitions. Mutagenesis by EMS and ENU was compared in a genetic suppressor screen of the rubber band phenotype induced by the *unc-93(e1500)* mutation.¹¹ Both mutagens produced revertants at similar frequencies but the types of alleles and the number of alleles per known suppressor gene were different. In particular, 90% of EMS point mutants were G/C to A/T transitions, which are more likely to produce stop codons rather than missense mutations. In contrast, the rate of A/T to G/C transitions was greatly increased with ENU. This analysis may be partially biased by the A/T richness of *unc-93* but has been largely confirmed by examining whole-genome sequencing data.^{12, 13} Interestingly, UV/TMP treatment appears to induce all types of transitions and transversions, with almost no bias.¹² EMS is the most powerful mutagen causing 1.5 to 2 times more mutations than ENU and more than 3 times more variations than UV/TMP. Which mutagen to choose will therefore be determined by the type of desired mutations. EMS remains the best choice to obtain null alleles, however ENU generates the biggest diversity of missense alleles which can sometimes be more informative for functional studies. Gamma, UV and X-ray irradiation cause major chromosomal rearrangements and have been mostly used to generate duplications, inversions, deficiencies and translocations.⁹

Classical mutant mapping

Classically, mutants have been mapped to a genetic interval by a combination of the following techniques (extensively reviewed in “Genetic mapping and manipulation”, www.wormbook.org): (1) Two- or three-point mapping with genetic markers;¹⁴ (2) Mapping with deficiencies and duplications;¹⁵ (3) Single Nucleotide Polymorphism (SNP) mapping.¹⁶

Two- or three-point mapping with genetic markers relies on the measure of the genetic distance (i.e. recombination frequency) between phenotypic mutants (with known physical positions) and the gene to be mapped. This approach can be used to rapidly assign a given mutation to a chromosomal region, however it lacks resolutions due to the relatively small number of such “landmark” mutants. In addition, genetic interactions between the landmark mutant and the target gene can sometimes complicate mapping. Similarly, deficiencies and duplications are not always precisely defined at their extremities. Classical genetic mapping was therefore rapidly supplanted by the introduction of SNP mapping techniques.

SNP mapping in *C. elegans* is based on the sequence divergence between the reference strain N2 *Bristol* and the CB4856 Hawaiian strain.¹⁷ SNPs occur on average every 1,000 base pairs. Most SNPs are indeed single nucleotide changes, but small insertions or deletions are also common. SNPs which lead to restriction-fragment length polymorphisms can be easily detected by restriction digests while “silent” SNPs need to be sequenced. SNP mapping can rapidly assign mutants to a chromosome¹⁸ and narrow down the position of a mutation of interest to relatively few candidate ORFs. Note however that an analysis of the CB4856 Hawaiian strain by array comparative genome hybridization has revealed 141 deletions removing 1.54 Mb of DNA and 483 predicted genes from CB4856’s genome.¹⁹ In addition, complex genetic interactions²⁰ and phenotypic variation of mutants in the *Bristol* or *Hawaiian* background can sometimes confuse mapping results. These and other limitations have encouraged the development of novel gene cloning techniques described in the next section.

New approaches for mapping mutants

Traditional mapping strategies can be time-consuming undertakings depending on the phenotypic complexity (e.g. tedious to score, variable phenotype, low penetrance) and genetic nature (e.g. suppressor or enhancer mutant) of the studied mutant. Two “next generation” technologies circumvent these problems.

Array Comparative Genome Hybridization—Array Comparative Genome Hybridization (aCGH) was first developed in *C. elegans* to accelerate the identification of “indel” (insertion/deletion) mutants for the *C. elegans* Knockout Consortium.¹⁹ It uses high density oligonucleotide microarrays (~380,000 probes/array) to detect sequence polymorphisms (SNP, indels) for the entire genome or specific regions of interest. The great sensitivity of aCGH allows the detection of heterozygous deletions as small as 141 bp. The resolution is directly related to the extent of the overlap between 50mer oligonucleotides on the array. In addition, aCGH can map a mutation to a small chromosomal interval (~200 – 400 kb) by analyzing the SNP distribution in homozygous mutants resulting from a single genetic cross of *Hawaiian* and N2 strains.²¹ In theory this approach should also be able to resolve polygenic traits.

Beyond SNP and deletion mapping, aCGH can directly detect homozygous single nucleotide mutations.²² To maximize the chances of detection, a maximum probe distance of less than 5 nucleotides is recommended. Given the probe capacity of the array, a mutation should therefore be mapped to a 1 Mb interval prior to aCGH, in order to achieve the highest probe density on both strands. Alternatively, multiple sub-arrays could be used to further increase coverage. For reference, aCGH has been successfully used to detect two single base lesions in the promoter of the *cog-1* gene.²³

Whole-Genome Sequencing—The most recent paradigm shift for *C. elegans* researchers is the development of whole-genome sequencing (WGS) methods. The first *C. elegans* mutant cloned by WGS (*Isy-12(ot177)*) was reported in 2008.²⁴ *Isy-12(ot177)* was initially mapped by a single SNP mapping cross to a 4 Mb region of chromosome V containing ~1100 genes. Paired-end Illumina sequencing generated 3.1 Gb of mapped reads resulting in ~28-fold genome coverage. Analysis and filtering of these sequences produced a list of 80 candidate variants which were tested by Sanger sequencing. This list was further reduced to four candidates by focusing on exonic mutations and by comparing variants between the *Isy-12(ot177)* mutant strain and the N2 strain used for outcrossing. Only one of the four polymorphisms was a nonsense mutation and mapped to the *Isy-12* gene. This demonstrated for the first time the feasibility of gene cloning by rough mapping and WGS.

The strengths of WGS are evident. (1) It is fast. Sequencing currently takes ~5 days and data analysis a few hours using optimized bioinformatic tools such as MAQgene²⁵ or galign.²⁶ (2) It is highly cost effective. Given the comparatively small size of the *C. elegans* genome (~100 Mb) and recent technology advances, a genome can be sequenced for less than US \$1,000. This expense compares favorably with the time, personnel and reagent cost involved for classical mapping and is also expected to drop even much further. (3) It greatly simplifies cloning of mutants with subtle, low penetrance or difficult to score phenotypes. Multigenic, quantitative or behavioral genetic traits which are sensitive to genetic backgrounds and therefore hard to map by conventional approaches will be much more accessible with WGS. (4) In addition to point mutations, WGS is also able to detect deletions depending on sequencing depth.¹³ (5) Sequencing errors are negligible when sufficient coverage is reached, reducing the risks of false negatives. (6) As it is relatively easy to obtain sufficient amounts of DNA, the technology can also be used for analyzing lethal mutants. For example, a homozygous lethal mutant in the *Isy-22* gene could be cloned by sequencing DNA extracted from a few hundred hand-picked, sterile worms.²⁷

Chemical mutagenesis generates hundreds of sequence variants per genome.^{12, 13} Initially, genetic mapping information was therefore considered crucial, unless independent alleles of the same gene were available for WGS. A novel one-step strategy that combines SNP mapping and whole-genome sequencing has recently been described (see Fig. 1).²⁸ Instead of focusing only on a few manually analyzed SNPs, this approach can theoretically take advantage of every SNP in the genome. The mutant strain isolated in an N2 *Bristol* background is first crossed with the polymorphic CB4856 *Hawaiian* strain and 20 to 50 mutant F2 recombinants are picked to single plates. These *Bristol/Hawaiian* recombinant lines are then pooled and analyzed by WGS. Chromosomal regions which are linked to the mutation are characterized by a strong increase in the *Bristol* to *Hawaiian* SNP ratio. In this proof-of-principle study, the SNP mapping information defined a ~2 Mb region, which only contained three protein-coding sequence variants.²⁸

Another strategy takes advantage of the fact that phenotype-relevant EMS mutations should cluster around the mutation of interest after outcrossing (see Fig. 1).²⁹ Rather than using the polymorphic *Hawaiian* strain, mutants retrieved from a genetic screen are backcrossed four to six times with the original strain used for mutagenesis. Their complete genome sequences are aligned to the N2 reference genome and variants which are common between at least two mutant strains (i.e. background mutations) are filtered out. Hotspots containing typical EMS mutations can then be detected by plotting sequence variants along chromosomes, highlighting the likely position of the mutant gene (see Fig. 1). Finally, analysis of individual variants provides a list of candidate genes which can be validated by other approaches such as phenotypic rescue, RNAi or analysis of additional alleles by Sanger sequencing.

Transposon-based insertional mutagenesis

Transposons are mobile DNA elements present in the genomes of all living organisms. While mobile elements are less efficient than chemical mutagens (see below), the resulting mutants can be more easily cloned because the transposon sequence serves as a molecular tag. This advantage will be less striking in the future, given the rapid development of whole-genome sequencing. However, transposons have unique and powerful downstream applications, i.e. generating custom deletions and engineering the genome.

Endogenous Transposons

Tc1 was the first transposable element identified in *C. elegans* and a founding member of the *Tc1/mariner* superfamily.³⁰ These class II elements move throughout the host genome

via a “cut-and-paste” mechanism in which a specific transposon-encoded transposase binds the two terminal inverted repeats of the transposon and catalyses its excision and reinsertion into a TA dinucleotide. In wild-type strains, *Tc* transposons are only mobile in somatic cells. However, “mutator” backgrounds can lift germline silencing³¹ and allow insertional mutagenesis using *Tc* elements. In 1985, long before any of the genome project tools were available, Iva Greenwald cloned the first *C. elegans* gene, *lin-12/Notch*, by using a transposon-tagging and chromosome walking approach.³² Subsequently, many genetic screens were performed with *TcI* and the localization of mutagenic *TcI* insertions was further simplified by the development of a “transposon-insertion display” technique.^{33–36}

While *TcI* has been a useful tool for forward genetic screens, some limitations have hampered its routine use: (1) Transposition in mutator backgrounds is an uncontrolled process. Most mutator backgrounds derepress all classes of *TcI/mariner* transposons and lead to an accumulation of transposon copies in the genome, making it harder to identify the mutagenic insertion. (2) *Tc* mutants are inherently unstable in mutator backgrounds. Spontaneous mobilization of a mutagenic insertion can sometimes lead to imprecise excision of the transposon leaving a DNA footprint which can remain mutagenic but is no longer linked to a transposon. (3) *TcI* transposons can be spliced out of pre-mRNAs.³⁷ This results in a mature mRNA that either contains small insertions of *TcI* sequences and/or lacks gene sequences at the spliced junctions.

Given these limitations, a number of labs have attempted to mobilize heterologous transposons in the *C. elegans* germline (*Himar*, *Sleeping Beauty*, *Minos*). However, all of these transposons could only be mobilized in somatic cells so far. However, one publication reports heritable insertions of the medaka fish transposon *ToI1*.³⁸ Although this system needs to be further characterized, it could serve as the basis for the a gene delivery system since, contrary to *TcI/mariner* transposons, *ToI1* can carry exogenous sequences and still be reasonably active.³⁹ To date, the only efficient transposon mutagenesis strategy using a heterologous transposon is based on the mobilization of the *Drosophila mauritiana* element *Mos1*.^{40, 41}

Mos1 Transposon Mutagenesis

Mos1 is a member of the *TcI/mariner* transposon family. It only requires its transposase but no host cell factor for transposition. Therefore, it has been possible to mobilize *Mos1 in vitro* and in a number of evolutionarily distant species.^{42, 43} The *Mos1* sequence is absent from the *C. elegans* genome making it a unique molecular feature which can be easily identified by standard molecular biology techniques (see Fig. 2).⁴⁴ *Mos1*-containing strains can be outcrossed against N2 or any other N2 derived background, removing all unlinked copies. *Mos1* transposons are only active when the *Mos1* transposase is provided. Therefore, *Mos1* insertions are stable in the genome once the source of transposase has been lost. Finally, a study of over 900 insertions demonstrated no strong insertional bias of *Mos1* except for a site on chromosome I.⁴⁵

Mos1 mutagenesis is based on a binary system (see Fig. 2).^{40, 44} Two extrachromosomal transgenes are used: one that contains multiple copies of the *Mos1* transposon (transposon array), and another that provides the transposase under the control of a heat-shock inducible promoter (transposase array). When the transposase activity is induced in doubly transgenic worms, *Mos1* can jump from the “transposon array” into the genome. The extrachromosomal arrays are lost in subsequent generations, eliminating the risk for *Mos1* re-excision. *Mos1* is approximately 10 times less efficient than EMS as a mutagen under optimal conditions.⁴⁶ This low efficiency has to be contrasted with the ease, speed and precision with which *Mos1* can be located.⁴⁴ *Mos1* transposons in a given strain can be quickly mapped by inverse PCR and sequencing of the *Mos1*-flanking genomic regions,

revealing their location with single base pair precision (see Fig. 2). On average, 2.5 insertions (range from 1 to 10) can be found per animal, making it easy to genetically associate a given insertion with a mutant phenotype. *Mos1* has been used successfully in different forward genetic screens.^{47–50} In addition, *Mos1* mutagenesis can also be used in *C. briggsae*, a related nematode species useful for comparative functional studies.⁵¹ Most importantly, each *Mos1* insertion can be used as a starting point to engineer the genome, as described in detail later in this review.

Automating genetic screens

There are many clever ways to perform genetic screens in *C. elegans*⁵² but many of them still rely on a researcher sitting for innumerable hours behind a microscope sifting through mountains of worms. In contrast, “high throughput” screens make it possible to (1) approach genetic saturation, (2) use less efficient mutagens (e.g. transposons) and (3) increase the chances of finding rare and unusual alleles (e.g. temperature-sensitive, hyper-, anti- or neomorphic alleles). Recently, certain screens have been automated using “worm sorters” and microfluidic devices.

The COPAS (Complex Object Parametric Analyzer and Sorter) Biosort machine (Union Biometrica) can sort hundreds of worms per minute, based on fluorescence, optical density or length. It is used to distribute worms into multiwell plates, for example for high-throughput screening of chemical libraries^{53, 54} or to generate *C. elegans* libraries.⁵⁵ But its most powerful feature is the ability to measure fluorescence profiles along the length of the animal at two different wavelength. This has allowed for example to analyse spatiotemporal promoter activity,⁵⁶ identify mutants required for the execution of neuronal cell fates,⁵⁷ or screen for genes involved in the innate immune response of *C. elegans* to pathogens.⁵⁸

Although the COPAS sorter is able to distinguish fluorescence changes along the body axis, it is not adapted for high-resolution analysis. Microfluidic devices have now been developed that allow automated screening of live *C. elegans*.^{59, 60} Worms can be automatically loaded into “worm chips”, mechanically immobilized, imaged at high-resolution and sorted based on complex phenotypic criteria with high accuracy. However, these elaborate systems require more processing time, with throughput still being significantly smaller than the COPAS worm sorter. Alternatively, approaches combining high resolution confocal microscopy and image analysis software could be adapted for some screening approaches. By taking advantage of the reproducibility of the *C. elegans* cell lineage and anatomy, it was possible for example to automatically assess the expression profiles of ~100 genes in ~400 cells of L1 stage larvae⁶¹ and to analyse gene expression during embryonic development with single-cell resolution.⁶²

REVERSE GENETICS

With the completion of the worm’s genome sequence over a decade ago,⁸ reverse genetic approaches have become increasingly popular. Instead of searching for genes implicated in a given process by phenotype (“forward genetics”), the goal of reverse genetics is to characterize the function of a selected gene by inactivating the expression of the gene either by RNAi or by isolating a loss-of-function allele.

Manipulating gene activity by RNAi

RNA interference (RNAi) was first discovered in *C. elegans*,^{7, 63} rapidly generalized to all other model systems from plants to vertebrates and recognized as a revolutionary approach to modify gene expression with potential medical applications. RNAi immediately became an attractive gene knock-down technology in *C. elegans*. With RNAi and the complete genome sequence, it was theoretically possible for the first time to easily and rapidly test the

function of a large number of genes in a systematic fashion. This led to remarkable large scale screens for cytokinesis,⁶⁴ essential genes and cell polarity,⁶⁵ lifespan,⁶⁶ fat regulation⁶⁷ and gene function at the whole-genome level.^{68, 69} Hundreds of genes gained new functions through RNAi-based studies. However it also became clear that not all genes were affected by RNAi and affected genes often did not show phenotypes as strong as corresponding genetic null mutants. Intriguingly, RNAi seemed to be much more efficient in certain tissues, with neurons being often refractory to RNAi. This surprising result led researchers to investigate the basis for this tissue specificity and identify sensitized mutant backgrounds which display increased RNAi sensitivity.^{70–75}

RNAi can be applied at any stage during development, which makes it easier to study essential genes or to study a gene's function at different stages of development. Double-stranded RNA (dsRNA) can be efficiently delivered in worms by four protocols.^{76, 77} Worms can either be (1) injected with *in vitro*-transcribed dsRNA;⁷ (2) soaked in buffer containing concentrated *in vitro*-transcribed dsRNA;⁷⁸ (3) fed bacteria expressing dsRNA from an engineered plasmid;^{79–81} (4) transformed with a vector expressing dsRNA in a given tissue.^{82–84} Injection of dsRNA into the gonad of young adult hermaphrodites, yields the greatest number of affected progeny. Surprising at first, injection into the intestine or body cavity also produces phenotypes in the progeny due to systemic RNAi.⁸⁵ Younger larvae may also be injected when the effect of RNAi needs to be tested on the injected animal and not its progeny. Following injection, the effect of RNAi lasts several days, affecting the adult progeny of an injected worm. Recently, an approach has been developed which allows temperature-dependent induction of RNAi using the *mec-8*-dependent regulation of *mec-2* intron 9 splicing.⁸⁶ In addition, expressing the transmembrane protein *SID-1*⁸⁵ in neurons has been found to increase neuronal response to dsRNA delivered by feeding.⁸⁷ Finally, clones for ~94% of all *C. elegans* genes are available from RNAi feeding libraries generated by the Ahringer and Vidal labs and can be procured from commercial suppliers (Source BioScience LifeSciences and Open Biosystems, respectively).

A few limitations of RNAi have to be kept in mind however: (1) A major disadvantage of RNAi compared to genetic mutation is the variable efficiency and potency of RNAi depending on the experimental conditions. (2) It is not possible to assess unambiguously the degree to which a gene's function is knocked down by RNAi. This is a significant caveat when interpreting RNAi results. (3) As discussed previously, some tissue types are insensitive to RNAi in the wild-type context but sometimes also in sensitized backgrounds. (4) The efficiency of RNAi decreases rapidly when multiple genes are targeted at once, limiting genetic interactions tests based solely on RNAi. (5) A given RNAi clone can sometimes target more than one gene, based on sequence similarity.⁸⁸ If no mutant allele is available to confirm an RNAi result, it is important to conduct RNAi with distinct non-overlapping dsRNA sequences derived from the target gene to avoid off-target effects.⁸⁹

Inhibition of microRNA function by antisense oligoribonucleotides

MicroRNAs (miRNA) constitute a large number of specialized, non-protein coding regulatory genes.⁹⁰ Their function can not be easily manipulated by conventional RNAi. When no genetic mutant is available for a miRNA of interest, its function can be inhibited by injecting antisense 2'-O-methyl oligoribonucleotides. Injection of these antisense compounds into larvae phenocopies *let-7* loss-of-function defects.⁹¹ However, injection into adult hermaphrodite gonads does not result in efficient miRNA inhibition suggesting that antisense oligoribonucleotides are not transmitted to the progeny efficiently. This approach was recently optimized by cross-linking antisense 2'-O-methyl oligoribonucleotides to dextran, a soluble polysaccharide.⁹² These novel antisense conjugates can be conveniently injected into hermaphrodite gonads and their effects assessed in the progeny up to late larval stages. Conjugated oligoribonucleotides have been shown to efficiently inhibit miRNA

function in hypodermis, vulva and neurons. Their effect is dose-dependent and highly specific. In addition, multiple miRNA can be targeted at once by mixing antisense reagents conjugated with different antisense oligoribonucleotides. This could facilitate the study of miRNA families and address potential functional redundancy.

Generating deletion mutants

Obtaining mutants by deletion library screening—Deletion libraries contain large numbers of worms organized in small pools that have been mutagenized with a deletion-inducing agent such as UV/TMP or EMS (see Fig. 3).^{93–95} When a deletion is of sufficient size, it can be detected by PCR with primers flanking the region of interest. Once a pool is found that reproducibly tests positive for a deletion, the worms in the pool are separated and rescreened until a single animal carrying the deletion is isolated. Two groups in the *C. elegans* community generate such mutants upon request: the Mitani Lab⁹⁶ and the *C. elegans* gene knock-out consortium⁹⁷ in Vancouver. So far, alleles for over 6000 genes have been generated by these two groups (Don Moerman, personal communication). Mutant strains are available from these consortia at a small fee and/or can be ordered from the CGC strain repository. In addition, individual labs can use published protocols to setup libraries to screen for gene deletions using EMS⁹⁸ or TMP/UV mutagenesis.^{77, 99} Building and screening a deletion library is a fairly large-scale project which is best suited when multiple genes are targeted.

Deletion mutants are very useful but a few issues need to be kept in mind: (1) worms retrieved from a library have been heavily mutagenized and usually carry many mutations in their genetic background, sometimes closely linked with the deletion of interest. (2) The size of the deletion is random and usually in the range of few hundred bases, which can be a problem for large genes and result in alleles which are not molecular nulls. (3) The endpoints of the deletion cannot be chosen, but only framed by the position of the screening primers. (4) Some deletions causing sterility or lethality can be difficult to recover and need to be stabilized using genetic balancers.⁹⁹ (5) Some deletions can be complex rearrangements that are difficult to characterize.

Obtaining deletion mutants by transposon mobilization

Spontaneous Tc1 excision: Although *Tc1* elements are fairly large DNA sequences which should disrupt gene function entirely, this is not always the case (see above). It is therefore important to derive a deletion mutant by remobilization of the transposon. In mutator backgrounds, deletions are generated at a low frequency after imprecise excision of the transposon. Most likely these events result from interrupted gene conversions with the sister strand.¹⁰⁰ This can be used as an alternative to deletion library screening when a *Tc1* transposon insertion is already available at an appropriate position in the gene. Such insertions can come from *Tc1*-based screens, specific PCR-based strategies targeted to a gene of interest,¹⁰¹ or from *Tc1* mutant collections (CGMC, Lyon, France;³⁶). This technique offers little to no control over the final structure of the deletion. In addition, PCR screening can be complicated by the frequent mobilization of somatic *Tc1* insertions which can be confused with heritable germline events and require additional sib-selection steps. Finally, uncontrolled jumping of *Tc1/mariner* transposons in the mutator background is accompanied by increased morbidity of the progeny and the possibility of novel transposon insertions closely linked to the deletion site. To circumvent some of these limitations, a protocol has been developed to precisely engineer genomic deletions or *gfp* insertion alleles by transgene-instructed gene conversion.¹⁰² This strategy is based on an earlier protocol¹⁰³ with a few optimizations: (1) two mutator backgrounds with increased *Tc1* excision rates (*mut-2* and *mut-7* vs. *mut-6*) were used; (2) the total length of sequence homology was increased from 3 kb to 9 kb. These modifications increased the frequency of transgene-

instructed gene conversion events significantly (4×10^{-4}), however no further study has been published since this initial report.

Mos1 transposon remobilization: Generating deletion alleles through *Mos1* transposon mobilization (MosDEL) is, in our opinion, the superior technique for this purpose (see Fig. 4). In order to put this technique in context with other *Mos1*-related techniques (*MosTIC* and *MosSCI*), we will discuss this approach in the “Genome engineering” section below.

Obtaining spontaneous deletions in the dog-1 mutant background—G4 DNA (guanine-quadruplex DNA) is a sequence motif that can fold into quadruplex structures in vitro. *In vivo*, such stable secondary structures can be problematic for DNA and RNA polymerases. Consistently, G4 DNA motifs have been identified as highly mutagenic sites in *dog-1* mutant animals.^{104, 105} *dog-1* is the *C. elegans* ortholog of the mammalian DNA helicase FANCI, which is mutated in Fanconi anemia patients. There are 2907 sites matching the G4 DNA signature in the *C. elegans* genome. In a proof of principle study, candidate sites were chosen to isolate deletion mutants in 10 genes. In brief, 96 pools of *dog-1(pk2247)* mutant worms were grown to starvation. After DNA isolation, each pool was screened by PCR for deletions 5' of various G4 DNA sites. This approach led to the isolation of 11 deletion alleles for the 10 targeted genes. This strategy could be generalized to the 1642 genes that are located 5' of to the 2907 G4 DNA sites. Approximately three quarters of these genes had no available alleles at the time of the study.¹⁰⁵

Generating targeted deletions by spontaneous gene conversion—Spontaneous recombination events between an engineered DNA template and a targeted genomic locus are extremely rare in *C. elegans*, most likely because injected DNA preferably forms extrachromosomal arrays and is therefore less available from homologous recombination. Early on, spontaneous gene conversion was obtained by injecting DNA into meiotic oocytes of individual worms which is technically challenging.^{106, 107} Another strategy has used microparticle bombardment to deliver a recombination template to a very large number of worms with little hands-on work.^{108, 109} The recombination template is composed of two homology arms which define the deletion end-points and flank a positive selection marker (*unc-119(+)*). In practice, this approach relies on generating hundreds of integrated lines in a *unc-119(ed3)* mutant background and selecting the rare homologous recombination events. When this strategy was used to disrupt the *unc-54* and *unc-22* genes, 1 and 3 homologous recombination events from 400 and 274 integrated lines were retrieved respectively.¹⁰⁸ This strategy was recently refined by “tagging” the bombardment plasmid with a *gfp* reporter gene (located outside the homology arms) which makes it easy to distinguish recombination events from non-homologous integrations events¹¹⁰. In addition, FLP recombination sites were added upstream and downstream of *unc-119(+)* to create “clean” mutants by removing the cassette using tissue-specific FRT expression. Unfortunately, it was impossible to delete the *unc-119* cassette in the germline and no further report using the technique has been published since.

Genome-scale identification of point mutations

Although chemical mutagens such as EMS can generate deletions (generally small and at a low frequency), they overwhelmingly induce point mutations in the genome. Two approaches have been devised to identify point mutants in individual genes throughout the entire genome.

TILLING: Targeting Induced Local Lesions in Genomes—TILLING aims to identify single nucleotide changes in target genes in a library of randomly mutagenized worms. PCR-amplified DNA from control and mutagenized worms is hybridized and

digested with a single-strand-specific nuclease. Digested fragments are detected via the fluorescently-labeled primers used for amplification. The position of the mutation can be estimated by determining the size of the resulting DNA fragment on a denaturing polyacrylamide LI-COR gel. Using a library of 1,500 mutagenized worms, TILLING was successfully used to identify 71 mutations in 10 target genes. 3% are putative null alleles and 59% result in missense mutations. The remaining mutants are silent.¹¹¹ TILLING appears not to have been used in *C. elegans* since this initial study.

Target-selected mutagenesis by high-throughput resequencing—Nonsense mutations can be identified from a library of mutagenized worms by cost-optimized high-throughput resequencing of target genes.¹¹² First, a clonal library of 6,144 mutagenized F1 animals was generated and cryopreserved. Next, gene regions of interest were amplified by nested PCR and sequenced. Calculations based on a pilot screen suggest that knockout mutations for over 90% of *C. elegans* genes are present in this library. Furthermore, if every nonsynonymous amino acid change is taken into account, then every eighth amino acid of the proteome should be mutated. In order to reduce the screening complexity, the authors propose to only target genomic positions called NIMs (nonsense introducing mutations). Since 93% of EMS mutations are G to A transitions and based on the size of the ORFeome (~24 Mb), only 500,000 NIMs should be targeted in the genome. Theoretically, this could now be achieved by aCGH or even whole-genome sequencing.

Genome editing using sequence specific nucleases: ZFNs and TALENs

Genome editing using *in vitro*-engineered Zn finger nucleases (ZFNs)¹¹³ and TALE-based hybrid nucleases (TALENs)^{114, 115} has been recently demonstrated in *C. elegans*.¹¹⁶ These proteins combine a tailor-made DNA binding module with the endonuclease domain of the *FokI* enzyme (Fig. 4). Recognition of specific DNA sequences by a nuclease dimer is followed by DNA cleavage between the two DNA binding sites. Imprecise repair of this double-strand break, usually through error-prone non-homologous end-joining, results in small deletions or insertions of a few base pairs at the target locus, thereby likely disrupting the function of the targeted sequences, such as genes or *cis*-regulatory elements.¹¹⁶

Genome editing in *C. elegans* is a four step process. First, two complementary nucleases that recognize a specific site in the genome must be designed, constructed and validated. Next, 5' and 3' UTR sequences favorable for germline translation are added to maximize the expression of the enzymes in the *C. elegans* germline. This artificial ORF is then transcribed *in vitro* to obtain highly concentrated, 5' capped, messenger RNA. Finally, RNA mixtures of the two complementary nucleases are directly injected into the gonad using the same procedure as for DNA germline transformation. Mutant alleles can then be selected in the F1 or F2 progeny of an injected animal. In the proof-of-principle study, mutant alleles were found in one percent of the total progeny of an injected animal (5% if an optimal 4-hour time window was considered).¹¹⁶ Whole genome analysis of one mutant strain revealed no off-target, ZFN-related lesions, confirming the very high specificity of this strategy. ZFN-based editing was also successfully applied to generate mutations in the related nematode species *C. briggsae*.¹¹⁶

Even though operating by similar overall principles, the TALE-based nucleases are more straight-forward to design, hence more cost-effective and will likely be the future method of choice. Different genome editing strategies which are used in other model systems¹¹³ could be adapted for *C. elegans* to allow for very precise genome engineering (Fig. 4D).

Engineering the genome: from single base changes to complex gene modification

The goal of genome engineering is to mutate a gene of interest or to modify a genomic locus by introducing *in vitro*-engineered sequences that, for example, contain affinity or reporter tags or alter the activity or localization of a gene. As mentioned previously, spontaneous gene conversion events are extremely rare in *C. elegans*. One efficient way to increase the rate of homologous recombination is to induce double-strand breaks (DSB) by reexcising a transposon. Two types of transposons have been successfully used in *C. elegans*: endogenous *Tc1* and *Drosophila Mos1*.

Chromosomal double-strand breaks are catastrophic events which can be resolved using multiple cellular mechanisms.¹¹⁷ In brief, either DSBs are repaired either by using homology of DNA sequences flanking the breakpoint (gene conversion) or by religation of free DNA ends (non-homologous end-joining, NHEJ). If the break produces cohesive ends, NHEJ will restore the wild-type sequences. If the lesion is blunt, partial digestion and religation by NHEJ will introduce small footprints. When a homologous recombination pathway is used, 5' to 3' exonucleases digest DNA to generate single-stranded DNA regions which can carry out homology scanning. If this single stranded region anneals inappropriately within the same chromosome, DNA synthesis from this position and subsequent religation will generate a deletion around the DSB site. However this single stranded region can also anneal with a homologous donor on a different DNA fragment such as sister chromatids, homologous chromosomes or engineered homologous templates. In the later case, artificial sequences can then be incorporated into the chromosome at the DSB site via gene conversion, resulting in a modified genomic locus and engineered alleles.

Transgene-instructed genomic engineering upon Tc1 excision—Genome engineering in a template-dependent manner was first reported by Plasterk and Groenen.¹⁰³ A strain containing a mutagenic *Tc1* insertion in the *unc-22* locus was micro-injected with a wild-type repair template containing silent sequence polymorphisms close to the *Tc1* insertion site. These markers were flanked by 1.5 kb of homologous sequences to drive recombination. Phenotypic revertants of the Unc-22 phenotype were selected from the progeny of these transgenic animals and analysed. The observed reversion frequency was low (2×10^{-5}) but three quarters of the revertants had incorporated sequence polymorphism up to ~200 bp from the DSB. This approach and an optimized protocol¹⁰² have however remained proof-of-principle experiments.

MosTIC: Mos1 excision induced Transgene Instructed gene Conversion—*MosTIC* is the first robust strategy that allows genome engineering in *C. elegans* in a targeted and controlled fashion (see Fig. 4).¹¹⁷ *Mos1* excision is used to create a genomic double-strand break at the engineered locus. This DSB is then repaired by gene conversion using an *in vitro*-engineered template which is provided on an extrachromosomal transgene. A detailed protocol has been published recently.¹¹⁸ *MosTIC* is preceded by a *Mos1* mutagenesis screen (see above) which provides the necessary transposon insertions. Alternatively, a large collection of *Mos1* alleles has been generated and mapped by the NemaGENETAG consortium (searchable on WormBase).^{55, 119} For efficient *MosTIC*, *Mos1* insertions should be chosen as close as possible to the target site. Indeed, the frequency of *MosTIC* events decreases in a bell shaped curve as a function of the distance from the *Mos1* insertion site. Point mutations have been introduced up to 3 kb away from the insertion site but with a 20-fold lower efficiency than at the insertion site itself.¹¹⁷ A point mutation contained within a 1 kb-long region centered on the DSB will be transferred into the genome in 50% of *MosTIC* events.

The *MosTIC* repair template is composed of two homology arms of 1.5 kb which flank the target region and the *Mos1* insertion site. The rate of *MosTIC* does not seem to increase when longer homology sequences are used¹¹⁷. This template is injected into the *Mos1* carrying strain with one of two vectors used to trigger *Mos1* transposase expression in the germline: (1) a heat-shock inducible construct using the *Phsp-16.48* promoter (*Phsp-16.48::MosTase*); (2) a construct using the constitutive germline promoter *Pglh-2* (*Pglh-2::MosTase*). In the first case, transgenic lines are established and amplified. Once sufficient transgenic animals are available, adult worms are heat-shocked and their progeny is screened for gene conversion events. *MosTIC* frequency generally ranges from 10^{-3} to 10^{-5} events per offspring of the heat-shocked animals. In the second case, gene conversion events can be detected in the F1 progeny of injected animals but more animals need to be injected since at best 1/10 will produce a *MosTIC* progeny.¹¹⁸

MosTIC events can be detected either by phenotypic reversion¹¹⁷ or by PCR screening.⁴⁹ Note that not all phenotypic reversion events will be *bona fide MosTIC*. Indeed, DSBs repaired by NHEJ can sometimes regenerate functional alleles. In the case of PCR screening strategies, false positives can arise from PCR jumping.¹¹⁷ Therefore, PCR screening conditions should be optimized carefully beforehand.¹¹⁸ *MosTIC* has been used successfully to insert point mutations,¹¹⁷ fluorescent tags,^{49, 117} epitopes for commercial antibodies⁴⁹ and affinity tags (unpublished). Such *MosTIC* alleles seem to replicate gene expression and protein localization with high accuracy and fidelity.⁴⁹

MosDEL: Mos1-mediated deletion—The goal of MosDEL is to generate *in vitro*-designed deletions around a *Mos1* insertion site in the genome (see Fig. 4).¹²⁰ Based on available strains in WormBase (> 14,000), 99.4% of the 20,160 *C. elegans* genes are within 25 kb of at least one *Mos1* insertion making them theoretically all targetable. Of these, 8,803 have no other genes between them and *Mos1* so only the targeted gene would be removed. In addition, all *Mos1* alleles obtained by insertional mutagenesis are usable for MosDEL.

The first step of MosDEL is to combine a *Mos1* strain with the *unc-119(ed3)* mutant. These worms are then injected with a DNA mix containing (1) mCherry-expressing vectors (used to identify false positives due to extrachromosomal array formation), (2) the source of *Mos1* transposase (*Pglh-2::MosTase*) and (3) the deletion template. The deletion template contains the *C. briggsae unc-119(+)* gene flanked by two homology arms which define the planned deletion end-points. When the *Mos1*-induced double-strand break is repaired using this transgene, the target region is deleted and *Cbr-unc-119(+)* is copied into the locus. This rescues the *unc-119(ed3)* mutation and results in a perfectly balanced deletion allele (see Fig. 4).

Approximately 100 P0 worms should be injected for MosDEL. In a proof-of-principle experiment aimed at deleting a 25 kb region close to the *dpy-13* locus, injection of 81 animals resulted in 7 stable lines carrying a *Cbr-unc-119(+)* fragment (9%).¹²⁰ Four of these seven lines were complete deletions of the 25 kb region (5%). No complete deletion of 35 or 50 kb could be recovered however. MosDEL currently appears as the most efficient tool to engineer precise gene deletions in the *C. elegans* genome.

Recent experiments show that antibiotics neomycin¹²¹ and puromycin¹²² can be used as efficient selection markers in worms. Current efforts to facilitate MosDEL focus on using antibiotic markers (Christian Frøkjær-Jensen & Erik M. Jørgensen, pers. comm.) which will eliminate the need to carry an *unc-119* mutation in the background.

EXPRESSING GENES IN *C. ELEGANS*

There are numerous reasons to introduce genes in *C. elegans*, including reporter gene analysis, transformation rescue of mutant phenotypes, manipulation of cell function, *et cetera*.

Classical *C. elegans* transgenesis

Transformation of *C. elegans* was first reported in the early 1980 in a study of the sex determination gene *tra-3*.¹²³ Kimble *et al.* microinjected an amber codon-suppressing tRNA (*sup-7(st5)*) into the hermaphrodite gonad of *tra-3* mutants carrying an amber allele which resulted in suppression of the Tra-3 phenotype in the progeny. Integrative¹⁰⁷ and non-integrative¹²⁴ DNA-mediated transformation was derived from this approach soon after.

DNA transformation by microinjection is a very fast, simple, inexpensive and efficient way to generate transgenic *C. elegans* strains.^{5, 10, 124} Injection requires little to no preparation and only few worms need to be injected to obtain transgenic lines. The *C. elegans* hermaphrodite germline is a syncytium containing hundreds of mitotically active oocytes at different stages of maturation and almost all nuclei share a common cytoplasm. Different DNA species can be co-injected (plasmids, PCR products, cosmids, fosmids, BACs, YACs) with selectable injection markers (fluorescent reporter genes, dominant or recessive phenotypic markers). This DNA mix will be processed by DNA end ligation and homologous recombination into large, heritable DNA concatemers called extrachromosomal arrays.^{5, 124} These episomes are recognized by the replication machinery and usually segregate like chromosomes during cytokinesis and meiosis. Detailed transgenesis protocols can be found here¹²⁵ and here (see Jin in¹⁰).

The ease with which these transgenes can be generated has to be balanced against the limitations of this approach: (1) Classical transgenesis offers little to no control over expression levels. Extrachromosomal transgenes generally contain hundreds of copies of the transforming DNA and therefore almost always result in overexpression. To obtain a more physiological result, the concentration of a given DNA species can be reduced by diluting it with more carrier DNA. (2) The highly repetitive nature of extrachromosomal transgenes leads to silencing in the germline.¹²⁶ This effect can be limited by generating “complex arrays” by co-injecting digested genomic DNA, preferably from a bacterial source. (3) Transgenes can rarely recreate the full genomic context and regulatory sequences necessary for accurate gene expression. Strikingly, the linear or circular nature of the injected DNA can influence the resulting expression patterns, with linear, vector-free DNA producing more accurate results.¹²⁷ (4) Extrachromosomal arrays can evolve over time. In particular, their expressivity and stability can change rapidly between generations.¹²⁴ It is therefore recommended to freeze transgenic lines as soon as possible and return to the original isolate if necessary. (5) Extrachromosomal arrays are semi-stable and not all progeny of a transgenic animal will inherit the transgene. Therefore they require manual maintenance unless a selectable co-injection marker is used. For example, transgenic animals can be generated in a *pha-1(e2123ts)* mutant background. These *pha-1* mutants are viable at 15°C but require the wild-type *pha-1* gene to survive at 25°C.¹²⁸ Very recently, two groups have developed antibiotic selection systems that can be used in any genetic background. Neomycin (or G-418)¹²¹ and puromycin¹²² are translation inhibitors which prevent the larval development of *C. elegans*. Ubiquitous expression of the corresponding resistance genes allows hands-off selection of transgenic animals and robust enrichment of large transgenic populations.

Stable integration of *C. elegans* transgenes

Integrative transgenesis was first achieved by injecting DNA into the nuclei of maturing oocytes.^{106, 107} Some integration events have also been reported when single-stranded oligonucleotides of 50 bases are co-injected with double-stranded DNA.⁵ However, these approaches are inefficient or technically challenging. Therefore, transgene integration is generally achieved by irradiating extrachromosomal lines with gamma or UV radiation (see Jin in¹⁰ and¹²⁵). Transgene sequences are randomly integrated into the genome, most likely following erroneous repair of a chromosomal break. The resulting stable lines need to be extensively outcrossed to remove background mutations. Moreover, it is recommended to obtain independent integrated lines since some variability in expression can be observed, likely due to positional effects and the amount of integrated DNA.

Stable transformation by microparticle bombardment

Microparticle bombardment has been used successfully in *C. elegans* to generate single to low-copy integrated transformant.^{129, 130} Gold beads coated with DNA are projected at high velocity at the sample allowing penetration into cells. The small amount of DNA on each bead likely decreases the chances of extrachromosomal array formation, therefore favoring integration events. Bombardment lines show more reproducible gene expression than extrachromosomal lines, but some variability has been reported.¹³¹ This approach also allows expression of transgenes in the germline because the low copy number circumvents germline-silencing observed for multicopy extrachromosomal arrays.¹²⁶ The low integration frequency ($\sim 5 \times 10^{-5}$) requires a positive selection strategy (usually *unc-119(ed3)* rescue) and the use of large numbers of synchronized worms.¹²⁹ Detailed instructions for transformation by microparticle bombardment can be found in¹³².

MosSCI: Generating single-copy transgenes by homologous recombination

The goal of MosSCI (*MosI*-mediated single copy insertion) is to generate stable single-copy transgenic strains by transgene-instructed gene conversion (see Fig. 4).¹³¹ The MosSCI approach is based on *MosTIC*¹¹⁷ with some specific modifications: (1) MosSCI is performed at one of two genomic sites (on chromosome II and IV) which are located in the 3' regions of two opposing genes. Therefore insertions there should minimally disrupt gene function. (2) MosSCI uses positive and negative selection strategies to identify *bona fide* gene conversion events. (3) A toolbox of vectors is available to rapidly generate MosSCI constructs (<http://sites.google.com/site/jorgensenmossci/>), in particular for germline expression.¹³³

The first step for MosSCI is to build the recombination template. This vector contains two 1.5 kb long homology arms corresponding to one of the two genomic insertion site (see Fig. 4). These sequences flank the *C. briggsae unc-119(+)* gene used for positive selection and a multiple cloning site or two gateway *att* recombination sequences which are used to clone the transgene. Transgenes of 3 to 8 kb have been inserted into the genome using these vectors¹³¹ and unpublished results indicate that insert sizes can be as large as 17 kb (Frøkjær-Jensen and Jorgensen, personal communication). Transgene insertions generated by MosSCI should be designated by "Si" (following the unique laboratory identifier).

Two protocols can be used for MosSCI: (1) The direct insertion protocol: the MosSCI vector is co-injected with mCherry-expressing vectors and the *P_{glh-2}::MosTase* plasmid and recombination events are selected directly in the F2-F3 progeny of injected animals. This requires to inject at least 25–50 P₀ animals, of which 2 to 5 will generate a MosSCI allele. On average 60% of these lines will contain complete, single-copy inserts. (2) The selection-based insertion protocol: the MosSCI vector is co-injected with the *P_{hsp-16.48}::MosTase* construct, multiple vectors expressing *mCherry* in different tissues and a muscle-expressed

gain-of-function mutant of the *twk-18* potassium channel. MosSCI is triggered by heat-shocking these transgenic animals and *mCherry* and *twk-18* are used as counterselection markers to eliminate animals which rescue the Unc-119 phenotype but are not true MosSCI lines. The direct insertion protocol is generally much faster (~10 days vs. one month) and requires less hands-on time. However, the selection-based insertion protocol can be scaled up significantly and displays higher success rates.

MosSCI recombination events are detected by the phenotypic rescue of *unc-119(ed3)*. However, *unc-119(ed3)* mutant are fairly unhealthy and difficult to inject. Recently, an alternative strategy usable in any genetic background and based on neomycin resistance has been used successfully.¹²¹

Up-to-date information, detailed instructions, descriptions of reagents and strains can be found here (<http://sites.google.com/site/jorgensenmossci/>). Upcoming developments of this technique are: (1) vectors and strains for 5 new genomic sites; (2) an improved insertion method with a success rate above 50%; (3) a new, heat-shock inducible negative selection marker that simplifies the selection of insertion events; (4) in depth characterization of each site regarding its permissiveness for germline expression (Frøkjær-Jensen and Jorgensen, personal communication).

Spatial and temporal manipulation of gene expression

Cell-specific gene expression can be achieved easily in *C. elegans* using specific, heterologous promoter fragments and gene expression can be controlled temporally using broadly if not ubiquitously expressed heat-shock-induced promoters. One approach to achieve both temporal and spatial control has been to combine cell-specific rescue of a mutant defective in the heat-shock response (*hsf-1(sy441)*) with a transgene expressing a gene of interest under the control of a heat-shock-responsive promoter.¹³⁴ Gene induction is therefore restricted to the *hsf-1*-expressing cells. This two component system was used to express *gfp* in the pharynx and neurons. It functions at all developmental stages and only requires a 30 min heat shock treatment. GFP expression was seen 1 h after heat shock and remained visible for 24 h. This system can also be used to study gene function as exemplified by the rescue of the dye filling defect of a mutant defective in neuron cilium formation and function.¹³⁴

A second approach for controlled gene expression is based on the *mec-8*-dependent alternative splicing of *mec-2*.⁸⁶ MEC-8 is an RNA binding protein that regulates the formation of the long *mec-2a* mRNA by promoting exon 9–10 over 9–9' splicing. Hence, inclusion of the 9th *mec-2* intron into another gene confers *mec-8*-dependent regulation. Using the temperature sensitive *mec-8(ut218ts)* allele, it is possible to control splicing and gene expression by shifting worms from the restrictive (25°C) to the permissive (15°C) temperature. This approach was used to activate *yfp* expression in neurons, hypodermis and intestine. However, although *mec-8* is ubiquitously expressed early in development, it is restricted to some tissue types at later stages. Therefore *gfp* expression was seen in head and tail neurons but not in the ventral nerve cord, somewhat limiting this approach. A temperature sensitive *mec-8(ut218ts)* allele could be ectopically expressed in the targeted tissue to circumvent this limitation. By extension, this approach was used to selectively express genes in cells for which no specific promoters are known by using promoters with partially overlapping expression domains to express *mec-8(ut218ts)* and the targeted gene fused to the 9th *mec-2* intron.⁸⁶

Another approach is based on the use of FLP recombinases which allows for permanent induction of gene expression in any genetic background.^{110, 135, 136} The FLP enzyme catalyses the intra-molecular excision of DNA located between two FRT sites when they are

oriented in the same direction (“FLP-out”). FLP-out activity in *C. elegans* was demonstrated by removing a cassette containing a fluorescent protein and a transcriptional termination sequence flanked by FRT sites.^{135, 136} Induction of FLP expression using a heat shock promoter resulted in total or partial loss of the FRT-flanked sequences and the “activation” of the downstream open reading frame. This system was used as a lineage tracing tool, to induce cell-specific RNAi, express a dominant negative transcription factor¹³⁶ and to silence neurotransmission in a temporally and spatially controlled fashion using tetanus toxin.¹³⁵ Both publications provide vector toolkits that can be used to adapt these technologies to specific biological questions. Recently, somatic FLP-mediated recombination has been demonstrated in the context of a genomic knock-in allele generated by biolistic transformation.¹¹⁰

Building reporter gene constructs by fosmid recombineering

Determining a gene’s expression pattern is a necessary step in the characterisation of any *C. elegans* gene. This can be achieved by using transcriptional or translational *gfp* or *LacZ* reporters.⁶ Reporter gene strategies have been discussed in great detail in Ref. 137. High-throughput approaches were also made possible by the use of Gateway compatible vectors, in particular with the completion of the ORFeome¹³⁸ and Promoterome projects.¹³⁹ However, most of these reporters only contain a few kilobases of gene regulatory sequence, because of the technical limitations encountered when trying to manipulate much larger DNA sequences. Recently, three novel methods have been developed which use recombineering of fosmid clones or BACs to engineer more comprehensive reporter constructs (see Fig. 5).^{140–142}

A fosmid library containing over 15,000 clones each carrying ~40 kb long genomic fragments is now available for *C. elegans* (Don Moerman, personal communication). Clones can be searched on WormBase or using a dedicated tool (<http://elegans.bcgsc.ca/perl/fosmid/CloneSearch>), and obtained through Source BioScience LifeSciences. Given the good genome coverage (~6x) of this library, it is usually possible to obtain a fosmid in which the gene of interest is at the center, flanked by large portions of genomic DNA, therefore including most of the likely regulatory sequences. The most recently developed recombineering protocol¹⁴⁰ is fast (approximately one week), robust (owing to positive and negative selection steps) and requires little more than a freely available bacterial strain, minimal media, and a diverse set of cassettes including fluorescent proteins, affinity tags or bicistronic fluorescent reporters.¹⁴⁰ Injection of fosmid as complex arrays (typically digested recombineered fosmid at 10–15 ng/μl, digested co-injection marker (2–7 ng/μl) and digested bacterial genomic DNA (120–150 ng/μl)) generates arrays that usually show excellent germline expression.¹⁴⁰

Conclusion

C. elegans has not only been at the forefront as a model system to understand biological processes, but also at the forefront for establishing widely applicable technologies. GFP reporter technology and RNAi are already classic examples. A number of the techniques presented here will surely be further developed and significantly fine-tuned. For example, the recent introduction of antibiotic selection markers^{121, 122} offers much promise. Anticipated significant drops in the cost of whole genome sequencing will further popularize forward genetic screens but also provide reverse-generated (i.e. non-phenotype driven) allelic versions of many/most/all genes in the genome. The development of engineered *Mos1* transposable elements, able to carry large cargo, will greatly simplify the generation of single copy transgenes and allow gene trapping strategies. Finally, efficient genome editing and engineering will open the door to a range of new experimental approaches. So far, only *Mos1*-based genome engineering was sufficiently efficient to be used routinely.

The promise of ZFNs and TALENs lies in their ability to cause double-strand breaks with high efficiency and accuracy. Once this is combined with transgene-instructed repair, these nucleases and possibly other nucleases such as meganucleases¹⁴³ will become the premier tools to mutate, modify and restore genes and gene function in *C. elegans* and related nematodes.

References

1. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics*. 1974; 77:71–94. [PubMed: 4366476]
2. Sulston JE. Neuronal cell lineages in the nematode *Caenorhabditis elegans*. *Cold Spring Harb Symp Quant Biol*. 1983; 48:443–452. [PubMed: 6586366]
3. Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode, *Caenorhabditis elegans*. *Dev Biol*. 1977; 56:110–156. [PubMed: 838129]
4. White JG, Southgate E, Thomson JN, Brenner S. The structure of the nervous system of the nematode *Caenorhabditis elegans*. *Philosophical Transactions of the Royal Society of London B Biological Sciences*. 1986; 314:1–340.
5. Mello CC, Kramer JM, Stinchcomb D, Ambros V. Efficient gene transfer in *C. elegans*: extrachromosomal maintenance and integration of transforming sequences. *EMBO J*. 1991; 10:3959–3970. [PubMed: 1935914]
6. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. *Science*. 1994; 263:802–805. [PubMed: 8303295]
7. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature*. 1998; 391:806–811. [PubMed: 9486653]
8. The *C. elegans*-Sequencing-Consortium. Genome sequence of the nematode *C. elegans*: a platform for investigating biology. *Science*. 1998; 282:2012–2018. [PubMed: 9851916]
9. Epstein, HF.; Shakes, DC., editors. *Caenorhabditis elegans: Modern Biological Analysis of an Organism*. Vol. 48. Academic Press; 1995.
10. Hope, IA. *C. elegans: a practical approach*. Oxford: Oxford University Press; 1999.
11. De Stasio E, Lephoto C, Azuma L, Holst C, Stanislaus D, Uttam J. Characterization of revertants of *unc-93(e1500)* in *Caenorhabditis elegans* induced by N-ethyl-N-nitrosourea. *Genetics*. 1997; 147:597–608. [PubMed: 9335597]
12. Flibotte S, Edgley ML, Chaudhry I, Taylor J, Neil SE, Rogula A, Zapf R, Hirst M, Butterfield Y, Jones SJ, et al. Whole-genome profiling of mutagenesis in *Caenorhabditis elegans*. *Genetics*. 2010; 185:431–441. [PubMed: 20439774]
13. Sarin S, Bertrand V, Bigelow H, Boyanov A, Doitsidou M, Poole RJ, Narula S, Hobert O. Analysis of multiple ethyl methanesulfonate-mutagenized *Caenorhabditis elegans* strains by whole-genome sequencing. *Genetics*. 2010; 185:417–430. [PubMed: 20439776]
14. Fay D. Genetic mapping and manipulation: chapter 1--Introduction and basics. *WormBook*. 2006:1–12.
15. Fay D. Genetic mapping and manipulation: chapter 6--Mapping with deficiencies and duplications. *WormBook*. 2006:1–3.
16. Fay D, Bender A. SNPs: introduction and two-point mapping. *WormBook*. 2008:1–10. [PubMed: 18819170]
17. Wicks SR, Yeh RT, Gish WR, Waterston RH, Plasterk RH. Rapid gene mapping in *Caenorhabditis elegans* using a high density polymorphism map. *Nat Genet*. 2001; 28:160–164. [PubMed: 11381264]
18. Davis MW, Hammarlund M, Harrach T, Hullett P, Olsen S, Jorgensen EM. Rapid single nucleotide polymorphism mapping in *C. elegans*. *BMC Genomics*. 2005; 6:118. [PubMed: 16156901]
19. Maydan JS, Flibotte S, Edgley ML, Lau J, Selzer RR, Richmond TA, Pofahl NJ, Thomas JH, Moerman DG. Efficient high-resolution deletion discovery in *Caenorhabditis elegans* by array comparative genomic hybridization. *Genome Res*. 2007; 17:337–347. [PubMed: 17267812]

20. Seidel HS, Rockman MV, Kruglyak L. Widespread genetic incompatibility in *C. elegans* maintained by balancing selection. *Science*. 2008; 319:589–594. [PubMed: 18187622]
21. Flibotte S, Edgley ML, Maydan J, Taylor J, Zapf R, Waterston R, Moerman DG. Rapid high resolution single nucleotide polymorphism-comparative genome hybridization mapping in *Caenorhabditis elegans*. *Genetics*. 2009; 181:33–37. [PubMed: 18957702]
22. Maydan JS, Okada HM, Flibotte S, Edgley ML, Moerman DG. De Novo identification of single nucleotide mutations in *Caenorhabditis elegans* using array comparative genomic hybridization. *Genetics*. 2009; 181:1673–1677. [PubMed: 19189945]
23. O'Meara MM, Bigelow H, Flibotte S, Etchberger JF, Moerman DG, Hobert O. Cis-regulatory mutations in the *Caenorhabditis elegans* homeobox gene locus *cog-1* affect neuronal development. *Genetics*. 2009; 181:1679–1686. [PubMed: 19189954]
24. Sarin S, Prabhu S, O'Meara MM, Pe'er I, Hobert O. *Caenorhabditis elegans* mutant allele identification by whole-genome sequencing. *Nat Methods*. 2008; 5:865–867. [PubMed: 18677319]
25. Bigelow H, Doitsidou M, Sarin S, Hobert O. MAQGene: software to facilitate *C. elegans* mutant genome sequence analysis. *Nat Methods*. 2009; 6:549. [PubMed: 19620971]
26. Shaham S. *galign*: a tool for rapid genome polymorphism discovery. *PLoS One*. 2009; 4:e7188. [PubMed: 19779626]
27. Flowers EB, Poole RJ, Tursun B, Bashllari E, Pe'er I, Hobert O. The Groucho ortholog UNC-37 interacts with the short Groucho-like protein LSY-22 to control developmental decisions in *C. elegans*. *Development*. 2010; 137:1799–1805. [PubMed: 20431118]
28. Doitsidou M, Poole RJ, Sarin S, Bigelow H, Hobert O. *C. elegans* mutant identification with a one-step whole-genome-sequencing and SNP mapping strategy. *PLoS One*. 2010; 5:e15435. [PubMed: 21079745]
29. Zuryin S, Le Gras S, Jamet K, Jarriault S. A strategy for direct mapping and identification of mutations by whole-genome sequencing. *Genetics*. 2010; 186:427–430. [PubMed: 20610404]
30. Bessereau JL. Transposons in *C. elegans*. *WormBook*. 2006:1–13. [PubMed: 18023126]
31. Mori I, Moerman DG, Waterston RH. Analysis of a mutator activity necessary for germline transposition and excision of Tc1 transposable elements in *Caenorhabditis elegans*. *Genetics*. 1988; 120:397–407. [PubMed: 2848746]
32. Greenwald I. *lin-12*, a nematode homeotic gene, is homologous to a set of mammalian proteins that includes epidermal growth factor. *Cell*. 1985; 43:583–590. [PubMed: 3000611]
33. Korswagen HC, Durbin RM, Smits MT, Plasterk RH. Transposon Tc1-derived, sequence-tagged sites in *Caenorhabditis elegans* as markers for gene mapping. *Proc Natl Acad Sci U S A*. 1996; 93:14680–14685. [PubMed: 8962114]
34. Wicks SR, de Vries CJ, van Luenen HG, Plasterk RH. CHE-3, a cytosolic dynein heavy chain, is required for sensory cilia structure and function in *Caenorhabditis elegans*. *Dev Biol*. 2000; 221:295–307. [PubMed: 10790327]
35. Martin E, Laloux H, Couette G, Alvarez T, Bessou C, Hauser O, Sookhareea S, Labouesse M, Segalat L. Identification of 1088 new transposon insertions of *Caenorhabditis elegans*: a pilot study toward large-scale screens. *Genetics*. 2002; 162:521–524. [PubMed: 12242258]
36. van der Linden AM, Plasterk RH. Shotgun cloning of transposon insertions in the genome of *Caenorhabditis elegans*. *Comp Funct Genomics*. 2004; 5:225–229. [PubMed: 18629154]
37. Rushforth AM, Anderson P. Splicing removes the *Caenorhabditis elegans* transposon Tc1 from most mutant pre-mRNAs. *Mol Cell Biol*. 1996; 16:422–429. [PubMed: 8524324]
38. Kodama K, Takagi S, Koga A. The Toll element of the medaka fish, a member of the hAT transposable element family, jumps in *Caenorhabditis elegans*. *Heredity*. 2008; 101:222–227. [PubMed: 18506201]
39. Koga A, Shimada A, Kuroki T, Hori H, Kusumi J, Kyono-Hamaguchi Y, Hamaguchi S. The Toll transposable element of the medaka fish moves in human and mouse cells. *J Hum Genet*. 2007; 52:628–635. [PubMed: 17554475]
40. Bessereau JL, Wright A, Williams DC, Schuske K, Davis MW, Jorgensen EM. Mobilization of a *Drosophila* transposon in the *Caenorhabditis elegans* germ line. *Nature*. 2001; 413:70–74. [PubMed: 11544527]

41. Robert VJ, Bessereau JL. Manipulating the *Caenorhabditis elegans* genome using mariner transposons. *Genetica*. 2010; 138:541–549. [PubMed: 19347589]
42. Coates CJ, Jasinskiene N, Miyashiro L, James AA. Mariner transposition and transformation of the yellow fever mosquito, *Aedes aegypti*. *Proc Natl Acad Sci U S A*. 1998; 95:3748–3751. [PubMed: 9520438]
43. Gueiros-Filho FJ, Beverley SM. Trans-kingdom transposition of the *Drosophila* element mariner within the protozoan *Leishmania*. *Science*. 1997; 276:1716–1719. [PubMed: 9180085]
44. Boulin T, Bessereau JL. Mos1-mediated insertional mutagenesis in *Caenorhabditis elegans*. *Nat Protoc*. 2007; 2:1276–1287. [PubMed: 17546024]
45. Granger L, Martin E, Segalat L. Mos as a tool for genome-wide insertional mutagenesis in *Caenorhabditis elegans*: results of a pilot study. *Nucleic Acids Res*. 2004; 32:e117. [PubMed: 15310838]
46. Williams DC, Boulin T, Ruaud AF, Jorgensen EM, Bessereau JL. Characterization of Mos1-mediated mutagenesis in *Caenorhabditis elegans*: a method for the rapid identification of mutated genes. *Genetics*. 2005; 169:1779–1785. [PubMed: 15654093]
47. Ruaud AF, Bessereau JL. Activation of nicotinic receptors uncouples a developmental timer from the molting timer in *C. elegans*. *Development*. 2006; 133:2211–2222. [PubMed: 16672334]
48. Gally C, Eimer S, Richmond JE, Bessereau JL. A transmembrane protein required for acetylcholine receptor clustering in *Caenorhabditis elegans*. *Nature*. 2004; 431:578–582. [PubMed: 15457263]
49. Gendrel M, Rapti G, Richmond JE, Bessereau JL. A secreted complement-control-related protein ensures acetylcholine receptor clustering. *Nature*. 2009; 461:992–996. [PubMed: 19794415]
50. Yook K, Hodgkin J. Mos1 mutagenesis reveals a diversity of mechanisms affecting response of *Caenorhabditis elegans* to the bacterial pathogen *Microbacterium nematophilum*. *Genetics*. 2007; 175:681–697. [PubMed: 17151260]
51. Winter AD, Keskiäho K, Kukkola L, McCormack G, Felix MA, Myllyharju J, Page AP. Differences in collagen prolyl 4-hydroxylase assembly between two *Caenorhabditis* nematode species despite high amino acid sequence identity of the enzyme subunits. *Matrix Biol*. 2007; 26:382–395. [PubMed: 17321733]
52. Jorgensen EM, Mango SE. The art and design of genetic screens: *caenorhabditis elegans*. *Nat Rev Genet*. 2002; 3:356–369. [PubMed: 11988761]
53. Burns AR, Kwok TC, Howard A, Houston E, Johanson K, Chan A, Cutler SR, McCourt P, Roy PJ. High-throughput screening of small molecules for bioactivity and target identification in *Caenorhabditis elegans*. *Nat Protoc*. 2006; 1:1906–1914. [PubMed: 17487175]
54. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, Stanley EF, McCourt P, Cutler SR, Roy PJ. A small-molecule screen in *C. elegans* yields a new calcium channel antagonist. *Nature*. 2006; 441:91–95. [PubMed: 16672971]
55. Duverger Y, Belougne J, Scaglione S, Brandli D, Beclin C, Ewbank JJ. A semi-automated high-throughput approach to the generation of transposon insertion mutants in the nematode *Caenorhabditis elegans*. *Nucleic Acids Res*. 2007; 35:e11. [PubMed: 17164286]
56. Dupuy D, Bertin N, Hidalgo CA, Venkatesan K, Tu D, Lee D, Rosenberg J, Svrikapa N, Blanc A, Carnec A, et al. Genome-scale analysis of in vivo spatiotemporal promoter activity in *Caenorhabditis elegans*. *Nat Biotechnol*. 2007; 25:663–668. [PubMed: 17486083]
57. Doitsidou M, Flames N, Lee AC, Boyanov A, Hobert O. Automated screening for mutants affecting dopaminergic-neuron specification in *C. elegans*. *Nat Methods*. 2008; 5:869–872. [PubMed: 18758453]
58. Pujol N, Cypowyj S, Ziegler K, Millet A, Astrain A, Goncharov A, Jin Y, Chisholm AD, Ewbank JJ. Distinct innate immune responses to infection and wounding in the *C. elegans* epidermis. *Curr Biol*. 2008; 18:481–489. [PubMed: 18394898]
59. Chung K, Crane MM, Lu H. Automated on-chip rapid microscopy, phenotyping and sorting of *C. elegans*. *Nat Methods*. 2008; 5:637–643. [PubMed: 18568029]
60. Gilleland CL, Rohde CB, Zeng F, Yanik MF. Microfluidic immobilization of physiologically active *Caenorhabditis elegans*. *Nat Protoc*. 2010; 5:1888–1902. [PubMed: 21127483]

61. Liu X, Long F, Peng H, Aerni SJ, Jiang M, Sanchez-Blanco A, Murray JI, Preston E, Mericle B, Batzoglou S, et al. Analysis of cell fate from single-cell gene expression profiles in *C. elegans*. *Cell*. 2009; 139:623–633. [PubMed: 19879847]
62. Murray JI, Bao Z, Boyle TJ, Boeck ME, Mericle BL, Nicholas TJ, Zhao Z, Sandel MJ, Waterston RH. Automated analysis of embryonic gene expression with cellular resolution in *C. elegans*. *Nat Methods*. 2008; 5:703–709. [PubMed: 18587405]
63. Guo S, Kemphues KJ. *par-1*, a gene required for establishing polarity in *C. elegans* embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. *Cell*. 1995; 81:611–620. [PubMed: 7758115]
64. Gonczy P, Echeverri C, Oegema K, Coulson A, Jones SJ, Copley RR, Duperon J, Oegema J, Brehm M, Cassin E, et al. Functional genomic analysis of cell division in *C. elegans* using RNAi of genes on chromosome III. *Nature*. 2000; 408:331–336. [PubMed: 11099034]
65. Zipperlen P, Fraser AG, Kamath RS, Martinez-Campos M, Ahringer J. Roles for 147 embryonic lethal genes on *C. elegans* chromosome I identified by RNA interference and video microscopy. *EMBO J*. 2001; 20:3984–3992. [PubMed: 11483502]
66. Lee SS, Lee RY, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. A systematic RNAi screen identifies a critical role for mitochondria in *C. elegans* longevity. *Nat Genet*. 2003; 33:40–48. [PubMed: 12447374]
67. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. Genome-wide RNAi analysis of *Caenorhabditis elegans* fat regulatory genes. *Nature*. 2003; 421:268–272. [PubMed: 12529643]
68. Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J. Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference. *Nature*. 2000; 408:325–330. [PubMed: 11099033]
69. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, et al. Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature*. 2003; 421:231–237. [PubMed: 12529635]
70. Kennedy S, Wang D, Ruvkun G. A conserved siRNA-degrading RNase negatively regulates RNA interference in *C. elegans*. *Nature*. 2004; 427:645–649. [PubMed: 14961122]
71. Simmer F, Tijsterman M, Parrish S, Koushika SP, Nonet ML, Fire A, Ahringer J, Plasterk RH. Loss of the putative RNA-directed RNA polymerase RRF-3 makes *C. elegans* hypersensitive to RNAi. *Curr Biol*. 2002; 12:1317–1319. [PubMed: 12176360]
72. Wang D, Kennedy S, Conte D Jr, Kim JK, Gabel HW, Kamath RS, Mello CC, Ruvkun G. Somatic misexpression of germline P granules and enhanced RNA interference in retinoblastoma pathway mutants. *Nature*. 2005; 436:593–597. [PubMed: 16049496]
73. Schmitz C, Kinge P, Hutter H. Axon guidance genes identified in a large-scale RNAi screen using the RNAi-hypersensitive *Caenorhabditis elegans* strain *nre-1(hd20) lin-15b(hd126)*. *Proc Natl Acad Sci U S A*. 2007; 104:834–839. [PubMed: 17213328]
74. Lehner B, Calixto A, Crombie C, Tischler J, Fortunato A, Chalfie M, Fraser AG. Loss of LIN-35, the *Caenorhabditis elegans* ortholog of the tumor suppressor p105Rb, results in enhanced RNA interference. *Genome Biol*. 2006; 7:R4. [PubMed: 16507136]
75. Zhuang JJ, Hunter CP. Tissue specificity of *Caenorhabditis elegans* enhanced RNA interference mutants. *Genetics*. 2011; 188:235–237. [PubMed: 21385728]
76. Timmons L. Delivery methods for RNA interference in *C. elegans*. *Methods Mol Biol*. 2006; 351:119–125. [PubMed: 16988430]
77. Ahringer, J., editor. Reverse genetics. *WormBook*. 2006. Available at: <http://www.wormbook.org>
78. Maeda I, Kohara Y, Yamamoto M, Sugimoto A. Large-scale analysis of gene function in *Caenorhabditis elegans* by high-throughput RNAi. *Curr Biol*. 2001; 11:171–176. [PubMed: 11231151]
79. Timmons L, Fire A. Specific interference by ingested dsRNA. *Nature*. 1998; 395:854. [PubMed: 9804418]
80. Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in *Caenorhabditis elegans*. *Gene*. 2001; 263:103–112. [PubMed: 11223248]

81. Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J. Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in *Caenorhabditis elegans*. *Genome Biol.* 2001; 2:RESEARCH0002. [PubMed: 11178279]
82. Timmons L, Tabara H, Mello CC, Fire AZ. Inducible systemic RNA silencing in *Caenorhabditis elegans*. *Mol Biol Cell.* 2003; 14:2972–2983. [PubMed: 12857879]
83. Tavernarakis N, Wang SL, Dorovkov M, Ryazanov A, Driscoll M. Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. *Nat Genet.* 2000; 24:180–183. [PubMed: 10655066]
84. Esposito G, Di Schiavi E, Bergamasco C, Bazzicalupo P. Efficient and cell specific knock-down of gene function in targeted *C. elegans* neurons. *Gene.* 2007; 395:170–176. [PubMed: 17459615]
85. Winston WM, Molodowitch C, Hunter CP. Systemic RNAi in *C. elegans* requires the putative transmembrane protein SID-1. *Science.* 2002; 295:2456–2459. [PubMed: 11834782]
86. Calixto A, Ma C, Chalfie M. Conditional gene expression and RNAi using MEC-8-dependent splicing in *C. elegans*. *Nat Methods.* 2010; 7:407–411. [PubMed: 20364149]
87. Calixto A, Chelur D, Topalidou I, Chen X, Chalfie M. Enhanced neuronal RNAi in *C. elegans* using SID-1. *Nat Methods.* 2010; 7:554–559. [PubMed: 20512143]
88. Rual JF, Klitgord N, Achaz G. Novel insights into RNAi off-target effects using *C. elegans* paralogs. *BMC Genomics.* 2007; 8:106. [PubMed: 17445269]
89. Tursun B, Patel T, Kratsios P, Hobert O. Direct conversion of *C. elegans* germ cells into specific neuron types. *Science.* 2011; 331:304–308. [PubMed: 21148348]
90. Ambros V. microRNAs: tiny regulators with great potential. *Cell.* 2001; 107:823–826. [PubMed: 11779458]
91. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. *PLoS Biol.* 2004; 2:E98. [PubMed: 15024405]
92. Zheng G, Ambros V, Li WH. Inhibiting miRNA in *Caenorhabditis elegans* using a potent and selective antisense reagent. *Silence.* 2010; 1:9. [PubMed: 20359322]
93. Jansen G, Hazendonk E, Thijssen KL, Plasterk RH. Reverse genetics by chemical mutagenesis in *Caenorhabditis elegans*. *Nat Genet.* 1997; 17:119–121. [PubMed: 9288111]
94. Liu LX, Spoerke JM, Mulligan EL, Chen J, Reardon B, Westlund B, Sun L, Abel K, Armstrong B, Hardiman G, et al. High-throughput isolation of *Caenorhabditis elegans* deletion mutants. *Genome Res.* 1999; 9:859–867. [PubMed: 10508845]
95. Gengyo-Ando K, Mitani S. Characterization of mutations induced by ethyl methanesulfonate, UV, and trimethylpsoralen in the nematode *Caenorhabditis elegans*. *Biochem Biophys Res Commun.* 2000; 269:64–69. [PubMed: 10694478]
96. Mitani S. Nematode, an experimental animal in the national BioResource project. *Exp Anim.* 2009; 58:351–356. [PubMed: 19654432]
97. Moerman DG, Barstead RJ. Towards a mutation in every gene in *Caenorhabditis elegans*. *Brief Funct Genomic Proteomic.* 2008; 7:195–204. [PubMed: 18417533]
98. Lesa GM. Isolation of *Caenorhabditis elegans* gene knockouts by PCR screening of chemically mutagenized libraries. *Nat Protoc.* 2006; 1:2231–2240. [PubMed: 17406462]
99. Barstead RJ, Moerman DG. *C. elegans* deletion mutant screening. *Methods Mol Biol.* 2006; 351:51–58. [PubMed: 16988425]
100. Zwaal RR, Broeks A, van Meurs J, Groenen JT, Plasterk RH. Target-selected gene inactivation in *Caenorhabditis elegans* by using a frozen transposon insertion mutant bank. *Proc Natl Acad Sci U S A.* 1993; 90:7431–7435. [PubMed: 8395047]
101. Rushforth AM, Saari B, Anderson P. Site-selected insertion of the transposon Tc1 into a *Caenorhabditis elegans* myosin light chain gene. *Mol Cell Biol.* 1993; 13:902–910. [PubMed: 8380898]
102. Barrett PL, Fleming JT, Gobel V. Targeted gene alteration in *Caenorhabditis elegans* by gene conversion. *Nat Genet.* 2004; 36:1231–1237. [PubMed: 15502826]
103. Plasterk RH, Groenen JT. Targeted alterations of the *Caenorhabditis elegans* genome by transgene instructed DNA double strand break repair following Tc1 excision. *EMBO J.* 1992; 11:287–290. [PubMed: 1740110]

104. Kruisselbrink E, Guryev V, Brouwer K, Pontier DB, Cuppen E, Tijsterman M. Mutagenic capacity of endogenous G4 DNA underlies genome instability in FANCD1-defective *C. elegans*. *Curr Biol*. 2008; 18:900–905. [PubMed: 18538569]
105. Pontier DB, Kruisselbrink E, Guryev V, Tijsterman M. Isolation of deletion alleles by G4 DNA-induced mutagenesis. *Nat Methods*. 2009; 6:655–657. [PubMed: 19684597]
106. Broverman S, MacMorris M, Blumenthal T. Alteration of *Caenorhabditis elegans* gene expression by targeted transformation. *Proc Natl Acad Sci U S A*. 1993; 90:4359–4363. [PubMed: 8506273]
107. Fire A. Integrative transformation of *Caenorhabditis elegans*. *EMBO J*. 1986; 5:2673–2680. [PubMed: 16453714]
108. Berezikov E, Bargmann CI, Plasterk RH. Homologous gene targeting in *Caenorhabditis elegans* by biolistic transformation. *Nucleic Acids Res*. 2004; 32:e40. [PubMed: 14982959]
109. Jantsch V, Pasierbek P, Mueller MM, Schweizer D, Jantsch M, Loidl J. Targeted gene knockout reveals a role in meiotic recombination for ZHP-3, a Zip3-related protein in *Caenorhabditis elegans*. *Mol Cell Biol*. 2004; 24:7998–8006. [PubMed: 15340062]
110. Vazquez-Manrique RP, Legg JC, Olofsson B, Ly S, Baylis HA. Improved gene targeting in *C. elegans* using counter-selection and Flp-mediated marker excision. *Genomics*. 2010; 95:37–46. [PubMed: 19747540]
111. Gilchrist EJ, O'Neil NJ, Rose AM, Zetka MC, Haughn GW. TILLING is an effective reverse genetics technique for *Caenorhabditis elegans*. *BMC Genomics*. 2006; 7:262. [PubMed: 17049087]
112. Cuppen E, Gort E, Hazendonk E, Mudde J, van de Belt J, Nijman IJ, Guryev V, Plasterk RH. Efficient target-selected mutagenesis in *Caenorhabditis elegans*: toward a knockout for every gene. *Genome Res*. 2007; 17:649–658. [PubMed: 17416746]
113. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet*. 2010; 11:636–646. [PubMed: 20717154]
114. Mahfouz MM, Li L, Shamimuzzaman M, Wibowo A, Fang X, Zhu JK. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. *Proc Natl Acad Sci U S A*. 2011; 108:2623–2628. [PubMed: 21262818]
115. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, et al. A TALE nuclease architecture for efficient genome editing. *Nat Biotechnol*. 2011; 29:143–148. [PubMed: 21179091]
116. Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R, Miller JC, Leung E, Meng X, et al. Targeted Genome Editing Across Species Using ZFNs and TALENs. *Science*. 2011
117. Robert V, Bessereau JL. Targeted engineering of the *Caenorhabditis elegans* genome following Mos1-triggered chromosomal breaks. *EMBO J*. 2007; 26:170–183. [PubMed: 17159906]
118. Robert VJ, Katic I, Bessereau JL. Mos1 transposition as a tool to engineer the *Caenorhabditis elegans* genome by homologous recombination. *Methods*. 2009; 49:263–269. [PubMed: 19250968]
119. Bazopoulou D, Tavernarakis N. The NemaGENETAG initiative: large scale transposon insertion gene-tagging in *Caenorhabditis elegans*. *Genetica*. 2009; 137:39–46. [PubMed: 19343510]
120. Frokjaer-Jensen C, Davis MW, Hollopeter G, Taylor J, Harris TW, Nix P, Lofgren R, Prestgard-Duke M, Bastiani M, Moerman DG, et al. Targeted gene deletions in *C. elegans* using transposon excision. *Nat Methods*. 2010; 7:451–453. [PubMed: 20418868]
121. Giordano-Santini R, Milstein S, Svrikapa N, Tu D, Johnsen R, Baillie D, Vidal M, Dupuy D. An antibiotic selection marker for nematode transgenesis. *Nat Methods*. 2010; 7:721–723. [PubMed: 20729841]
122. Semple JJ, Garcia-Verdugo R, Lehner B. Rapid selection of transgenic *C. elegans* using antibiotic resistance. *Nat Methods*. 2010; 7:725–727. [PubMed: 20729840]
123. Kimble J, Hodgkin J, Smith T, Smith J. Suppression of an amber mutation by microinjection of suppressor tRNA in *C. elegans*. *Nature*. 1982; 299:456–458. [PubMed: 7121584]
124. Stinchcomb DT, Shaw JE, Carr SH, Hirsh D. Extrachromosomal DNA transformation of *Caenorhabditis elegans*. *Mol Cell Biol*. 1985; 5:3484–3496. [PubMed: 3837845]

125. Evans, TC., editor. Transformation and microinjection. WormBook. 2006. Available at: <http://www.wormbook.org>
126. Kelly WG, Fire A. Chromatin silencing and the maintenance of a functional germline in *Caenorhabditis elegans*. *Development*. 1998; 125:2451–2456. [PubMed: 9609828]
127. Etchberger JF, Hobert O. Vector-free DNA constructs improve transgene expression in *C. elegans*. *Nat Methods*. 2008; 5:3. [PubMed: 18165801]
128. Granato M, Schnabel H, Schnabel R. pha-1, a selectable marker for gene transfer in *C. elegans*. *Nucleic Acids Res*. 1994; 22:1762–1763. [PubMed: 8202383]
129. Praitis V, Casey E, Collar D, Austin J. Creation of low-copy integrated transgenic lines in *Caenorhabditis elegans*. *Genetics*. 2001; 157:1217–1226. [PubMed: 11238406]
130. Wilm T, Demel P, Koop HU, Schnabel H, Schnabel R. Ballistic transformation of *Caenorhabditis elegans*. *Gene*. 1999; 229:31–35. [PubMed: 10095101]
131. Frokjaer-Jensen C, Davis MW, Hopkins CE, Newman BJ, Thummel JM, Olesen SP, Grunnet M, Jorgensen EM. Single-copy insertion of transgenes in *Caenorhabditis elegans*. *Nat Genet*. 2008; 40:1375–1383. [PubMed: 18953339]
132. Strange, K., editor. *C. elegans: Methods and Applications*. Vol. 351. Humana Press; 2006.
133. Zeiser E, Frokjaer-Jensen C, Jorgensen E, Ahringer J. MosSCI and Gateway Compatible Plasmid Toolkit for Constitutive and Inducible Expression of Transgenes in the *C. elegans* Germline. *PLoS One*. 2011; 6:e20082. [PubMed: 21637852]
134. Bacaj T, Shaham S. Temporal control of cell-specific transgene expression in *Caenorhabditis elegans*. *Genetics*. 2007; 176:2651–2655. [PubMed: 17603102]
135. Davis MW, Morton JJ, Carroll D, Jorgensen EM. Gene activation using FLP recombinase in *C. elegans*. *PLoS Genet*. 2008; 4:e1000028. [PubMed: 18369447]
136. Voutev R, Hubbard EJ. A “FLP-Out” system for controlled gene expression in *Caenorhabditis elegans*. *Genetics*. 2008; 180:103–119. [PubMed: 18723890]
137. Boulin, T.; Etchberger, JF.; Hobert, O. Reporter gene fusions. WormBook. 2006. Available at: <http://www.wormbook.org>
138. Reboul J, Vaglio P, Rual JF, Lamesch P, Martinez M, Armstrong CM, Li S, Jacotot L, Bertin N, Janky R, et al. *C. elegans* ORFeome version 1. 1: experimental verification of the genome annotation and resource for proteome-scale protein expression. *Nat Genet*. 2003; 34:35–41. [PubMed: 12679813]
139. Dupuy D, Li QR, Deplancke B, Boxem M, Hao T, Lamesch P, Sequerra R, Bosak S, Doucette-Stamm L, Hope IA, et al. A first version of the *Caenorhabditis elegans* Promoterome. *Genome Res*. 2004; 14:2169–2175. [PubMed: 15489340]
140. Tursun B, Cochella L, Carrera I, Hobert O. A toolkit and robust pipeline for the generation of fosmid-based reporter genes in *C. elegans*. *PLoS One*. 2009; 4:e4625. [PubMed: 19259264]
141. Sarov M, Schneider S, Pozniakovski A, Roguev A, Ernst S, Zhang Y, Hyman AA, Stewart AF. A recombineering pipeline for functional genomics applied to *Caenorhabditis elegans*. *Nat Methods*. 2006; 3:839–844. [PubMed: 16990816]
142. Dolphin CT, Hope IA. *Caenorhabditis elegans* reporter fusion genes generated by seamless modification of large genomic DNA clones. *Nucleic Acids Res*. 2006; 34:e72. [PubMed: 16717278]
143. Arnould S, Chames P, Perez C, Lacroix E, Duclert A, Epinat JC, Stricher F, Petit AS, Patin A, Guillier S, et al. Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. *J Mol Biol*. 2006; 355:443–458. [PubMed: 16310802]



Figure 1. Mutant mapping by whole genome sequencing

(A) WGS-SNP mapping. A homozygous mutant strain (mutation denoted by a red diamond) in a Bristol background is crossed with a SNP-containing Hawaiian strain. Mutant worms segregating from this cross are reselected in the F2 generation. These mutant lines carry chimeric chromosomes (containing Bristol and Hawaiian SNPs) generated by meiotic recombination. When DNA from multiple F2 recombinant lines is pooled and sequenced, then the relative number of Bristol vs. Hawaiian SNP at a given location in the genome will be a reflection of the relative distribution of recombinants in the pool. Therefore, only Bristol SNPs will be found close to the mutation of interest (adapted from Ref. 28).

(B) Mapping based on mutagen-induced DNA variation density across the genome. Mutagenized strains contain not only mutagen-induced damage (orange asterisks) but also carry background variants (green crosses) present in the mother strain before mutagenesis.

By backcrossing a candidate mutant line to the strain used for the original mutagenesis, it is possible to eliminate most mutagen-induced lesions except for those which are closely linked to the phenotype-causing mutation (red diamond). In addition, background variation present in the unmutagenized strain can be identified by comparing independent backcrossed mutant lines. After filtering, the genomic region linked to the phenotype-causing mutation will be highlighted by a high-density cluster of mutagen-induced lesions (adapted from Ref. 29).




Figure 2. *Mos1*-based insertional mutagenesis

(A) *Mos1* can jump from an extrachromosomal transgene carrying multiple copies of the transposon into the genome, following the expression of the *Mos1*-specific transposase via a heat-shock inducible transgene. *Mos1* insertions are generally random in the genome but always takes place at a TA dinucleotide.

(B) *Mos1* insertions can be rapidly mapped with single nucleotide resolution by sequencing the flanking genomic sequences using an inverse PCR strategy (adapted from Ref. 44).




Figure 3. Generating deletion mutants by library screening

Populations of randomly mutagenized worms can be established using different mutagens and different culture strategies. Mutant strains are either preserved in a frozen library or conserved on NGM plates in a "live" library. To optimize library screening, DNA samples extracted from all worm cultures can be pooled according to different pooling schemes. Deletions with sizes ranging from 500 bp to 1,500 bp are detected by nested PCR screening. Shorter deletions can be detected more easily by including a poison-primer. Once a candidate pool has been identified, the corresponding well is thawed from the frozen library and all recovered worms are cloned on individual plates for secondary rescreening. Similarly, worms from a "live" library are recultured in small pools and single worms are picked from PCR-positive pools. Once a single worm harboring a deletion has been isolated, a few steps should be undertaken before the strain can be used for functional studies.




Figure 4. Genome editing with engineered nucleases

(A) Structure of a Zinc Finger (ZF) DNA-binding module. Each individual ZF domain is optimized to recognize a three base pair sequence. Two cysteines and two histidines coordinate a zinc atom in each module.

(B) ZF nucleases (ZFN) are composed of at least four ZF domain repeats, linked to the *FokI* endonuclease domain. Specificity is increased by using obligatory dimers of two ZFN recognizing two sites which flank the targeted double-strand break site.

(C) Structure of TALE nucleases (TALEN). A central array of tandem repeats forms the specific DNA binding domain. Two nucleotides (repeat-variable di-residues, RVD) in each repeat determine the sequence preference of each module. Examples of four RVDs that recognize all four nucleotides (NT) are indicated. Two TALEN monomers bind to their target sites and allow the dimerization of the *FokI* endonuclease domain. TALENs also contain a nuclear localization signal (NLS).

(E) ZFNs and TALENs allow different types of genome editing strategies. A double strand-break (DSB) can be resolved by different pathways. (i) A single DSB can be repaired by non-homologous end-joining (NHEJ) and result in a small deletion of a few base pairs. Alternatively, (ii) two simultaneous DSB can generate a larger deletion allele. When a repair template with homology regions is provided, the DSB is resolved by gene conversion to (iii) insert a small sequence (as small as a single nucleotide, i.e. “gene correction”) or (iv) a larger transgene (“gene addition”).




Figure 5. MosTIC, MosDEL and MosSCI strategies

(A) The double-strand break induced by the excision of *MosI* (i) can be repaired by *MosTIC* using different repair templates to engineer point mutations (ii), fusion proteins (iii), or gene deletions (iv). In the case of *MosDEL* (v), a *unc-119(+)* mini-gene is used as a positive selection marker.

(B) The goal of *MosSCI* is to engineer single copy transgenes at a defined location in the genome. A double-strand break induced by *MosI* excision is repaired by homologous recombination with an *in vitro*-engineered template which contains the desired transgene in combination with the *unc-119(+)* mini-gene.




Figure 6. *C. elegans* fosmid recombineering

Recombineering can be used to efficiently engineer a gene of interest in the context of a fosmid genomic clone. For example, a cassette containing a GFP tag and the FRT-*galK*-FRT selection module (FgF) can be inserted by λ Red recombinase-mediated homologous recombination into any position of a gene. Recombination is carried out in the SW105 *E. coli* strain. Recombinant clones are selected on minimal medium with galactose. Excision of the FgF selection module is carried out by Flp recombinase (induced by addition of arabinose) and can be selected for in medium containing deoxy-galactose. Note that the FRT "scar" remaining after *galK* excision resides in an intron and therefore has no impact on protein coding sequences. Additional applications of fosmid recombineering include: sequence deletion, sequence replacement and fosmid extension. A comprehensive set of recombineering cassettes including different fluorescent reporters, affinity tags, nuclear localization signals, mutant FRT sites and gene replacement cassettes is available (adapted from Ref. 140).